Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390982 | 0.88 | TSHR (0.71) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL26848353 | 0.73 | L3MBTL1 (0.62) | TSHRL3MBTL1CYP3A4CYP2C19MEN1 | |
| SCHEMBL26814652 | 0.70 | L3MBTL1 (0.57) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL27331238 | 0.70 | TSHR (0.66) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL7129560 | 0.69 | TSHR (0.65) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL7129555 | 0.69 | TSHR (0.65) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL20008962 | 0.69 | L3MBTL1 (0.64) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL4943200 | 0.69 | L3MBTL1 (0.64) | TSHRL3MBTL1CYP3A4CYP2C19MEN1 | |
| SCHEMBL26971194 | 0.69 | TSHR (0.59) | TSHRL3MBTL1CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL7346677 | 0.69 | MMP1 (0.54) | TSHRL3MBTL1CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093747-A1 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS | CELTAXSYS, INC. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093747-A1 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS | PMAIP1, CDC42, DCX | TSHR 4209/4885L3MBTL1 1285/4885CYP3A4 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.